The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The promise of CELMoDs in myeloma as monotherapy or in combination with other agents
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the potential of emerging cereblon E3 ligase modulators (CELMoDs), such as iberdomide and mezigdomide, for the treatment of multiple myeloma (MM). Dr Cerchione highlights that, to date, the safety and efficacy of these agents have been promising, and he believes they will provide an alternative therapeutic option for patients with relapsed/refractory (R/R) disease, both as monotherapy and in combination with carfilzomib or bortezomib. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
